445 related articles for article (PubMed ID: 25766951)
1. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Braunwald E
J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
[TBL] [Abstract][Full Text] [Related]
2. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
3. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
4. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Macdonald PS
Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
[TBL] [Abstract][Full Text] [Related]
5. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
6. LCZ696 : a new paradigm for the treatment of heart failure?
Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
[TBL] [Abstract][Full Text] [Related]
7. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
8. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
McMurray JJ
Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
10. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
Vardeny O; Tacheny T; Solomon SD
Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
[TBL] [Abstract][Full Text] [Related]
11. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
12. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Vardeny O; Miller R; Solomon SD
JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
[TBL] [Abstract][Full Text] [Related]
13. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Vaduganathan M; Desai AS
Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Gori M; Senni M
Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
[TBL] [Abstract][Full Text] [Related]
16. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
Książczyk M; Lelonek M
Heart Fail Rev; 2020 May; 25(3):393-402. PubMed ID: 31713710
[TBL] [Abstract][Full Text] [Related]
18. Neprilysin Inhibitors in Cardiovascular Disease.
Kang G; Banerjee D
Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
[TBL] [Abstract][Full Text] [Related]
19. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz M; Rizkala AR; Rouleau JL; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2014 Jul; 16(7):817-25. PubMed ID: 24828035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
